Zobrazeno 1 - 10
of 933
pro vyhledávání: '"niraparib"'
Autor:
Dana M. Chase, Soham Shukla, Julia Moore, Tirza Areli Calderón Boyle, Jonathan Lim, Jessica Perhanidis, Jean A. Hurteau, Jeanne M. Schilder
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 599-607 (2024)
Abstract Introduction Niraparib first-line maintenance (1LM) therapy has demonstrated clinical benefit for patients with ovarian cancer (OC) in clinical trial and real-world settings, but data on factors associated with real-world patient outcomes re
Externí odkaz:
https://doaj.org/article/877785eaaff34eb1860b79fe8e83b988
Autor:
Bobbie Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M. Schilder, Jean A. Hurteau, Amanda Golembesky
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 465-475 (2024)
Abstract Introduction Clinical trials have demonstrated prolonged survival associated with niraparib first-line maintenance (1LM) therapy, compared with placebo, for patients with ovarian cancer (OC). However, data are limited on real-world 1LM nirap
Externí odkaz:
https://doaj.org/article/be7e5d732cdc4346b5c2c634f5e5b807
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Purpose This study aims to investigate the effect of Niraparib in combination with an Anti-GD2 Antibody on osteosarcoma cells. Methods Scratch test was utilized to assess cell migration capacity, while the Transwell experiment was utilized t
Externí odkaz:
https://doaj.org/article/d59c7df4e7374661960841a2cde0e75e
Autor:
Qi Guan, Suriya J. Aktar, Reka E. Pataky, Mariet Mathew Stephen, Maud Marques, Karen Gambaro, Kahina Rachedi, Katharina Forster, Samara Strub, David Stock, Louis de Léséleuc, Winson Y. Cheung, Stuart Peacock, Christie Farrer, Scott Gavura, Mina Tadrous, Robert C. Grant, Kelvin K. W. Chan
Publikováno v:
Current Oncology, Vol 31, Iss 6, Pp 3591-3602 (2024)
Niraparib was recently funded in Canada for the maintenance treatment of ovarian cancer following platinum-based chemotherapy. However, the drug’s safety profile in the real world remains uncertain. We conducted a cohort study to describe the patie
Externí odkaz:
https://doaj.org/article/7817f7dbf22f4c7abc1ea613261997ef
Autor:
Ahmed Bilal Khalid, Christos Fountzilas, Heather N. Burney, Hirva Mamdani, Bryan P. Schneider, Christopher Fausel, Susan M. Perkins, Shadia Jalal
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionEsophageal adenocarcinoma (EAC) remains a devastating disease and second line treatment options in the metastatic space are limited. Homologous recombination (HR) defects have been described in EAC in up to 40% of patients. Poly (ADP-ribo
Externí odkaz:
https://doaj.org/article/19fc348440154b7ba0bfc880c85865d9
Autor:
Guojuan Sun, Yi Liu
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe landscape of poly (ADP-ribose) polymerase (PARP) inhibitor treatment for ovarian cancer (OC) is continually evolving. This research aimed to evaluate the efficacy and safety of PARP inhibitors compared to placebo as a maintenance therap
Externí odkaz:
https://doaj.org/article/32bbe5b73da74d1994c43187a85a90a8
Autor:
Jimmy Belotte, Brunella Felicetti, Amanda J. Baines, Ahmed YoussefAgha, Luis Rojas-Espaillat, Ana Godoy Ortiz, Diane Provencher, Raúl Márquez Vázquez, Lucia González Cortijo, Xing Zeng
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, has been shown to extend progression-free survival in patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based ch
Externí odkaz:
https://doaj.org/article/6a0a2a80b0c94cb1a14431371e664115
Autor:
Laura Hopkins, Mark Carey, Linda Brown, Sabryna McCrea, Mark Milne, Dawne Tokaryk, Dawn Stacey
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1416-1425 (2024)
New treatments for ovarian cancer are available that require trade-offs between progression-free survival and quality of life. The aim of this study was to develop a decision aid for patients with homologous recombinant proficient (HRP) tumors, as th
Externí odkaz:
https://doaj.org/article/b368cf527f034141bf61cfab142c3047
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundPre-clinical studies showed the anti-tumor mechanisms of PARP inhibitors (PARPi) and platinum have some crossover and overlap in the DNA damage repair pathway, patients who respond to platinum-based chemotherapy are also more likely to be s
Externí odkaz:
https://doaj.org/article/7358ee68c1f84e519dc402ec162b82dd
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundNiraparib, a poly ADP-ribose polymerase inhibitors (PARPi), has been widely applied in the intervention of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Nevertheless, as of the present moment, there are limited instances
Externí odkaz:
https://doaj.org/article/097232fbbb1c43739e915177a5c98a21